

# Macular Oxygen Saturation in Glaucoma Using Retinal Oximetry of Visible Light Optical Coherence Tomography

Jingyu Wang<sup>1</sup>, Natalie Sadlak<sup>2</sup>, Marissa G. Fiorello<sup>2</sup>, Manishi Desai<sup>2</sup>, Ji Yi<sup>1,3,4,\*</sup>

1. Department of Ophthalmology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA
  2. Department of Ophthalmology, Boston Medical Center, Boston, MA, USA
  3. Department of Medicine, Boston University School of Medicine, Boston Medical Center, Boston, MA, USA
  4. Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA
- Corresponding author: Ji Yi, [jiyi@jhu.edu](mailto:jiyi@jhu.edu)

## Abstract

**Purpose:** Oxygen saturation ( $sO_2$ ) plays a critical role in retinal pathophysiology, especially at the macula, which undergoes significant energy consumption. While macular damage has been suggested to be involved in early-stage glaucoma, there has been no report to date on non-invasive macular  $sO_2$  in glaucoma. Therefore, we conducted this study to compare macular  $sO_2$  associated with other clinical measurements between normal and glaucoma subjects and evaluate whether there are significant differences.

**Method:** This is a cross-sectional study. We used visible light optical coherence tomography (VIS-OCT) for retinal oximetry in perifoveal vessels. The subjects from groups of normal, suspect/pre-perimetric glaucoma (GS/PPG) and perimetric glaucoma (PG) were scanned using VIS-OCT in the macular region with a sampling density of  $512 \times 256$  in an area of  $5 \times 5$  mm<sup>2</sup>. 48 eyes (16 normal, 17 GS/PPG and 15 PG) were included for the analysis. For each eye, we measured the  $sO_2$  of arterioles ( $AsO_2$ ), venules ( $VsO_2$ ), and calculated the difference between arterioles and venules ( $A-V sO_2 = AsO_2 - VsO_2$ ), oxygen extraction ( $OE = (AsO_2 - VsO_2) / AsO_2 \times 100\%$ ). Additionally, we included Zeiss Cirrus OCT scans and 24-2 visual field test (VFT) for clinical benchmark. One-way ANOVA was used to compare the differences among the three groups. Spearman correlation tests were used for correlation  $sO_2$  markers to standard metrics including the thickness of ganglion cell layer and inner plexiform layer (GCL+IPL), circumpapillary retinal nerve fiber layer (cpRNFL) and mean deviation (MD) in VFT.

**Result:** Significant differences were found among three groups for all VIS-OCT, Zeiss OCT, and VFT variables. Macular  $AsO_2$ ,  $A-V sO_2$ , OE decreased, and  $VsO_2$  increased along with severity. Macular  $AsO_2$  and  $A-V sO_2$  were statistically correlated with GCL+IPL and cpRNFL in all eyes, as well as only PG eyes. Within PG eyes, the correlation between  $AsO_2$  and GCL+IPL is dominant in more damaged lower hemifield.

**Conclusion:** The GS/PPG and PG subjects had significantly higher macular  $VsO_2$ , lower  $A-V sO_2$  and OE indicating less oxygen consumption. The  $sO_2$  measured by retinal oximetry of VIS-OCT can be a potential metric for the early diagnosis of glaucoma.

**Keywords:** visible light optical coherence tomography, retina oximetry, glaucoma.

## Introduction

Glaucoma is an optical neuropathy, causing irreversible blindness and impacting millions worldwide<sup>1,2</sup>. The clinical hallmark of glaucoma is the loss of retinal ganglion cells (RGCs) and nerve fiber layer (RNFL), leading to chronic vision deterioration. Vision loss in glaucoma is permanent and irreversible, emphasizing the importance of early detection for prevention and clinical management<sup>3-6</sup>.

While the initial insult occurs at optic nerve head, it retrogradely damages the axon and soma of RGCs<sup>7</sup>. Because the macula contains >30% of total RGCs in retina<sup>8-10</sup>, changes associated with RGC damage may be detected in macular region. Indeed, evidence supported that early stages of glaucoma may involve macular RGC loss that warrants close attention<sup>8,11</sup>. Thinning of macular ganglion cell complex is associated with glaucoma<sup>12</sup>. Optical coherence tomography angiography found reduced macular superficial capillary density in glaucoma eyes, and the rate of capillary density can indicate glaucoma worsening in some cases<sup>13-15</sup>. Using a 10-2 VFT with denser 2° sampling density, a recent study showed central visual damage in over 30% of ocular hypertensive and glaucomatous eyes while the conventional 24-2 VFT appeared normal<sup>16</sup>.

The retina is one of the highest oxygen-consuming tissues, with RGCs being the major consumer in inner retina, perfused by retinal circulation<sup>17,18</sup>. Therefore, we hypothesize the macular inner retina oxygen extraction can assess RGC function, allowing the measurement of reduced oxygen extraction in the macular region to indicate the damage or loss of RGCs. By measuring blood sO<sub>2</sub> from parafoveal arterioles and venules extended from superior and inferior arcades towards macula, we can assess macular oxygen consumption by arteriovenous sO<sub>2</sub> (A-V sO<sub>2</sub>) and oxygen extraction.

To non-invasively measure macular vessel sO<sub>2</sub>, visible light optical coherence tomography (VIS-OCT) is used in this study. VIS-OCT is an emerging retinal imaging method that uses visible light instead of conventional near infrared (NIR), resulting in much higher axial resolution and significant absorption contrast between oxygenated and deoxygenated hemoglobin<sup>19-21</sup>. This makes retinal oximetry using VIS-OCT feasible for quantifying sO<sub>2</sub> in human eyes<sup>22-24</sup>. Compared to the existing Oximap based on multi-wavelength fundus images<sup>25-27</sup>, VIS-OCT provides unattainable depth-resolved capabilities, allowing for more precise measurement of sO<sub>2</sub> in macular vessels and even capillaries<sup>28</sup>.

Here, the goal of this presented study is to utilize retinal oximetry of VIS-OCT to measure macular sO<sub>2</sub> in normal, GS/PPG and PG groups, evaluate the feasibility of sO<sub>2</sub> to be an early biomarker to differentiate among these three groups, and explore the association between sO<sub>2</sub> and glaucoma-represented parameters of GCL+IPL and cpRNFL.

## Method




Figure 1  $sO_2$  maps and  $sO_2$  calculation (a-c)  $sO_2$  map of a right, left and right eyes from the Normal, GS/PPG, and PG subjects. (d-e) Fitting for calculating  $sO_2$  of arterioles and venules.

## Human subjects

The Institutional Review Board of Boston Medical Center reviewed and approved this study, ensuring compliance with the Health Insurance Portability and Accountability Act. The study took place from March 2019 to January 2020. All the subjects were provided with the tenets of Declaration of Helsinki, and written informed consent was obtained from each participant. We recruited the subjects in control group through the Boston Medical Center Optometry clinics, and the clinical subjects from in BMC eye clinics during their standard of care visit.

## Clinical examination

Prior to the examination, the pupils were dilated by Tropicamide. Subjects underwent tonometry, stereoscopic optic disc assessment and clinical OCT imaging (Cirrus, Zeiss, Jena, Germany). We recorded the quantitative results including cpRNFL and GCL+IPL, cup to disc ratio (CDR) and vertical cup-disc ratio (VCDR) from Cirrus OCT scans. For all the clinical subjects, central 24-2 threshold visual field tests (VFTs) were conducted with mean deviation (MD) and pattern standard deviation (PSD). We evaluated the cataracts using the Lens Opacification System II based on

color and opalescence utilizing a 4-point grading system with an increasing number consistent with increasing maturity. After clinical and ophthalmic examinations, a trained technician imaged the subjects using the dual-channel VIS-OCT system with both eyes if eligible.

We acquired the images centered at the fovea using a custom-built dual-channel VIS-OCT system<sup>29</sup> with a raster scanning of 512 A-lines by 256 B-scans covering an area of 5x5 mm<sup>2</sup>. The illumination wavelengths were 545 to 580 nm for the visible channel, and 800 to 880 nm for the NIR channel. The illumination power on pupil was less than <0.25 mW (VIS) and 0.9 mW (NIR), respectively, meeting the safety standards of the ANSI for ophthalmic instrument. Details of the calculation can be seen in the supplementals of our previous publication<sup>30</sup>. We used a tunable lens to correct the spherical refractive error. We used the fellow eye for fixation with an external target. The start of the imaging used the NIR channel for alignment and focus tuning. After confirming desired locations with the best preview image quality, we initiated the dual-channel acquisition. The A-line rate of camera is 50 kHz with an exposure time of 19.1 us. The total acquisition time for one raster scan was 2.62s.

### Image processing and sO<sub>2</sub> calculation

After acquisition, volumetric 3D data from both channels were produced by DC spectrum removal, k-space resampling, dispersion compensation and fast Fourier transform. Detailed processing steps are described in the past work<sup>24</sup>. In NIR dataset, we first segmented the layer of retinal pigment epithelium (RPE) by detecting the location of maximum intensity in each A-line, then detected the location of maximum gradient above the RPE layer for ILM boundary. We used outlier detection and 3<sup>rd</sup> order polynomial curve fitting to smooth the segmentation of RPE and ILM, then registered them in VIS data. We generated the *en face* vessel map by averaging the space between RPE and 20 pixels above RPE for the maximum contrast, then manually chose the vessels as vessel ROI mask.

Using short time Fourier transform, 11 Gaussian windows swept the interferogram for four-dimensional (4D) dataset  $I(x, y, z, \lambda)$ . A-lines within vessel ROIs were averaged for spectrum  $I(z, \lambda)$ , which is further normalized by an averaged spectrum from non-vascular RNFL. With the known ILM boundary, we located the vessel bottom and averaged the spectrum in depth from 5 pixels above the vessel bottom and 10 pixels below to generate a single spectrum for each vessel ROI.

A least-square fitting on the extracted spectra calculates sO<sub>2</sub> for each vessel ROI using the algorithm below as in **Figure 1**

$$I(sO_2 | \lambda, z) = I_0(\lambda) \sqrt{R_0 r(\lambda)} e^{-[sO_2 \times \mu_{HbO_2}(\lambda) + (1-sO_2) \times \mu_{Hb}(\lambda)]z} \quad (1)$$

where  $I_0(\lambda)$  is the spectrum of light source;  $R_0$  is an assumed constant for the reflectance of reference arm;  $r(\lambda)$  (dimensionless) is the reflectance at the vessel wall, modelled by a power law  $r(\lambda) = A\lambda^{-\alpha}$ , with A being a dimensionless constant and modelling the decaying scattering spectrum from the vessel wall. The optical attenuation coefficient  $\mu$  is determined by the coefficients of absorption  $\mu_a$  and scattering  $\mu_s$ , where  $\mu(\lambda) = \mu_a(\lambda) + W\mu_s(\lambda)$ .  $W$  is the scaling factor for the scattering coefficient which was 0.2 used here. After obtaining the sO<sub>2</sub> for all vessels, we classified them into the sO<sub>2</sub> of arterioles (AsO<sub>2</sub>) and venules (VsO<sub>2</sub>) based on the alternation pattern and values. We defined sO<sub>2</sub> difference between arterioles and venues (A-V sO<sub>2</sub>=AsO<sub>2</sub>-VsO<sub>2</sub>) and oxygen extraction (OE= (AsO<sub>2</sub> - VsO<sub>2</sub>)/AsO<sub>2</sub>\*100%) for further investigation.

## Study group definition

We defined a normal eye as one with a normal-appearing optical nerve head, assessed by stereoscopic optic disc photograph at the point of care (subjective assessment of vertical cup-disc ratio), and intraocular pressure (IOP)  $\leq 22$  mmHg. We defined the GS/PPG as an optical disk potentially presenting glaucomatous optical neuropathy after stereoscopic optic nerve examination. The visual field was normal by the 24-2 VFT threshold test, and the glaucoma hemifield test was within normal range or borderline. The index of pattern standard deviation was less than 5%. We defined the PG as an optic disc compatible with glaucoma. The subjects had an abnormal visual field, including the result of glaucoma hemifield outside the normal limit or the index of pattern standard deviation was less than 0.05%.

## Inclusion and exclusion criterion

We included subjects over 40 years old and with visual acuity better than 20/40 after correction. For the experimental group, we only included the patients diagnosed with primary open angle glaucoma (POAG) or potential POAG, excluding other ocular conditions such as primary angle closure glaucoma (PACG), intraocular surgeries (except for uncomplicated cataract surgery), history of diabetic retinopathy, vascular occlusion, macular degeneration, macular edema, hereditary retinal degeneration, uveitis, and other retinal conditions. We excluded the subjects from both groups due to fixation failure and low image quality that rendered them unattainable for segmentations. Subjects with severe cataracts graded more than 2+ were also excluded, considering the sensitivity of visible light to cataract and lens changes.

## Statistical analysis

We evaluated the categorical variables by Fisher-Freeman-Halton exact test and Chi-square test. For continuous variables, we applied one-way ANOVA across the three groups, followed by multiple comparisons. We employed the t-test for two group comparisons. We conducted the Receiver operating characteristic (ROC) analysis to assess detection accuracy based on the univariate logistic regression. We did the Spearman correlation test among the variables to get the correlation coefficients and p-values. It is noted as significant with bold when the  $p$  value was less than 0.05.

## Results

### Demographics

A total of 48 eyes of 35 subjects were included in the analysis: 16 eyes of 10 normal subjects, 17 eyes of 12 GS/PPG subjects and 15 eyes of 13 GS subjects. The primary reasons for exclusion were severe cataracts and fixation failure, which resulted in incomplete *en face* macular images and the inability to segment retinal layers for subsequent sO<sub>2</sub> analysis. The demographic was presented in **Table 1**. No significant differences were observed among the three groups regarding eye side, age, gender, race, and ethnicity.

Table 1 Demographic of subjects.

	Normal	GS/PPG	PG	P-value
Subjects(n)	10	12	13	-
Eyes (OD/OS)	8/8	8/9	8/7	0.939 (a)
Age (mean± standard deviation)	61.0±13.4	63.3±10.3	63.6±12.9	0.865 (b)
Gender (female/male)	5/5	6/6	7/6	0.976(a)

Race (AA/White/N.A.)	5/3/2	7/4/1	6/4/3	0.936 (c)
Ethnicity (non-Hispanic/Hispanic/N.A.)	7/2/1	11/1/0	11/1/1	0.727 (c)

AA: African American. N.A., not applicable. (a) Chi-square test. (2) One way ANOVA test. (c) Fisher-Freeman-Halton exact test

### Key measurements

Ocular measurements among three groups are summarized in **Table 2**. In visual field testing (VFT), the differences between GS/PPG and PG are significant for both 24-2 MD and 24-2 PSD. Additionally, all measurements obtained from Cirrus and VIS-OCT are all significantly different among three groups.

*Table 2 Characteristics of ocular measurements from eyes among three groups*

	Normal (n=16)	GS/PPG (n=17)	PG (n=15)	P-value
<b>Ophthalmic Exam</b>				
Cataract (Yes/No/N.A.)	9/7/0	10/6/1	13/0/2	<b>0.013</b> (a)
Pseudophakic lens (Yes/No/N.A.)	3/13/0	4/12/1	0/13/2	0.181 (a)
IOP (mean ± Std mmHg)	15.4 ± 2.3	14.8 ± 3.6	13.5 ± 3.8	0.321 (b)
Cylinder (mean ± Std)	1.00 ± 0.71	0.46 ± 0.37	0.83 ± 0.53	0.051 (b)
<b>Visual field test</b>				
24-2 MD (mean ± Std dB)	-	-0.59 ± 0.97	-7.60 ± 4.67	<b>&lt;0.001</b> (c)
24-2 PSD (mean ± Std dB)	-	1.91 ± 0.39	7.71 ± 4.63	<b>&lt;0.001</b> (c)
<b>Zeiss OCT</b>				
GCL+IPL (mean ± Std μm)	78.1 ± 8.9	73.8 ± 8.2	64.0 ± 11.3	<b>&lt;0.001</b> (b)
cpRNFL (mean ± Std μm)	90.9 ± 10.0	85.4 ± 15.2	70.4 ± 13.0	<b>&lt;0.001</b> (b)
Averaged CDR (mean ± Std μm)	0.42 ± 0.15	0.74 ± 0.09	0.73 ± 0.09	<b>&lt;0.001</b> (b)
VCDR (mean ± Std μm)	0.40 ± 0.17	0.72 ± 0.09	0.74 ± 0.10	<b>&lt;0.001</b> (b)
<b>sO<sub>2</sub></b>				
AsO <sub>2</sub> (mean ± Std vol%)	92.1 ± 7.1	88.5 ± 4.7	84.5 ± 9.3	<b>0.017</b> (b)
VsO <sub>2</sub> (mean ± Std vol%)	48.4 ± 5.0	57.2 ± 8.5	56.1 ± 10.8	<b>0.009</b> (b)
A-V sO <sub>2</sub> (mean ± Std vol%)	43.8 ± 9.5	31.4 ± 9.3	28.3 ± 9.7	<b>&lt;0.001</b> (b)
OE (mean ± Std %)	47.1 ± 7.5	35.3 ± 9.5	33.6 ± 10.1	<b>&lt;0.001</b> (b)

(a) Fisher-Freeman-Halton exact test. (b) One-way ANOVA test. (c) t-test. Bold indicates p<0.05

**Figure 2** illustrates the distribution of VIS-OCT measurements, including AsO<sub>2</sub>, VsO<sub>2</sub>, A-V sO<sub>2</sub>, OE, as well as Cirrus measurements of GCL+IPL and cpRNFL in each group. The mean value of AsO<sub>2</sub> demonstrates a decrease from normal to GS/PPG and further to PG. VsO<sub>2</sub> significantly increased from normal to GS/PPG and PG, but changed with no significant difference between GS/PPG and PG. A-V sO<sub>2</sub> and OE exhibit a decreasing trend with severity, indicating reduced oxygen extraction from macular perfusion; these differences were highly significant from normal to GS/PPG (P<0.01) and normal to PG (P<0.001). A-V sO<sub>2</sub> In Cirrus OCT thickness measurements, GCL+IPL and cpRNFL decrease with severity, consistent with literature. The significant differences occur from normal to GS/PPG and from GS/PPG to PG.




Figure 2 Statistical comparison among normal, GS/PPG and PG groups (a-d)  $AsO_2$ ,  $VsO_2$ , A-V  $sO_2$  and OE among three groups. (e-f) Zeiss OCT thickness including GCL+IPL and cpRNFL. One-way ANOVA was performed first, then multiple comparison within groups was to calculate the p value. ns, not significant,  $p > 0.05$ . \*,  $p < 0.05$ . \*\*,  $p < 0.01$ . \*\*\*,  $p < 0.001$ .

### Correlations of key parameters

We performed Spearman correlation among key parameters, including  $AsO_2$ ,  $VsO_2$ , A-V  $sO_2$ , OE, GCL+IPL, cpRNFL and MD, as shown in **Table 3**. Within the  $sO_2$  variables, there is no correlation between  $AsO_2$  and  $VsO_2$ . A-V  $sO_2$  and OE are correlated with  $AsO_2$  and  $VsO_2$ , as expected. Both GCL+IPL and cpRNFL are significantly correlated with  $AsO_2$ , A-V  $sO_2$  and OE. MD shows no correlation to the variables mentioned above.

Table 3 Correlations among groups for key measurements among three groups

	$AsO_2$	$VsO_2$	A-V $sO_2$	OE	GCL+IPL	cpRNFL
$VsO_2$	-0.053(0.722)					

A-V sO <sub>2</sub>	<b>0.570(0.000)</b>	<b>-0.788(0.000)</b>				
OE	<b>0.425(0.003)</b>	<b>-0.905(0.000)</b>	<b>0.968(0.000)</b>			
GCL+IPL	<b>0.341(0.019)</b>	-0.208(0.160)	<b>0.356(0.014)</b>	<b>0.316(0.031)</b>		
cpRNFL	<b>0.339(0.019)</b>	-0.170(0.253)	<b>0.363(0.012)</b>	<b>0.304(0.038)</b>	<b>0.742(0.000)</b>	
MD(a)	0.030(0.873)	0.021(0.911)	0.168(0.367)	0.081(0.704)	0.332(0.067)	0.343(0.059)

Correlation coefficient was calculated by the Spearman test. The number was bold when p-value < 0.05. (a) Correlation was done within suspect and glaucoma

We further investigated the same correlations but only within PG group shown in Table 4. Compared to the result in Table 3, GCL+NFL and cpRNFL are still correlated with AsO<sub>2</sub> and A-V sO<sub>2</sub>.

Table 4 Correlations for key measurements in PG

	As O <sub>2</sub>	VsO <sub>2</sub>	A-V sO <sub>2</sub>	OE	GCL+IPL	cpRNFL
VsO <sub>2</sub>	0.354(0.215)					
A-V sO <sub>2</sub>	0.279(0.334)	<b>-0.714(0.004)</b>				
OE	0.130(0.659)	<b>-0.824(0.000)</b>	<b>0.952(0.000)</b>			
GCL+IPL	<b>0.596(0.024)</b>	-0.077(0.794)	<b>0.546(0.044)</b>	0.460(0.098)		
cpRNFL	<b>0.581(0.029)</b>	-0.141(0.631)	<b>0.568(0.034)</b>	0.510(0.062)	<b>0.936(0.000)</b>	
MD(a)	-0.086(0.771)	-0.222(0.446)	0.226(0.436)	0.174(0.553)	0.407(0.149)	0.257(0.374)

Correlation coefficient was calculated by the Spearman test. The number was bold when p-value < 0.05.

In addition, we examined macular sO<sub>2</sub> by hemifields within PG eyes, as visual damage is preferentially more severe in the lower hemifield than the counterpart (Fig. 3a, 3b), with significantly lower MD. When comparing macular sO<sub>2</sub> with macular GCL+NFL, a significant correlation is found between AsO<sub>2</sub> and GCL+NFL in the low hemifield (Fig. 3c, 3d), while the same correlations in the upper hemifield were not significant. This analysis indicates AsO<sub>2</sub> is correlated with macular RGC loss with confirmed visual field damage.






Figure 3 Hemifield analysis in PG subjects. (a) The PG right eye with the deviation map, vision field map and GCL+IPL in different regions and. (b) The MD comparison in the lower and upper hemifields of PG subjects, (c-f) Scatter plot between AsO<sub>2</sub> and VsO<sub>2</sub> and GCL+IPL thickness in the lower and upper hemifields in PG subjects. Correlation coefficient and p-value were noted.

### Severity distinguishing

Table 5 illustrates the AUC results of ROC analysis to find the most effective parameter to distinguish among the three groups. All sO<sub>2</sub> parameters performed better than the GCL+IPL and cpRNFL in distinguishing subjects between normal and GS/PPG, particularly OE. The cpRNFL had the highest AUC area to differentiate GS/PPG from PG.

Table 5 Area Under the Curve (AUC) by ROC analysis.

	Normal vs GS/PPG	GS/PPG vs. PG	Normal vs. GS/PPG + PG
AsO <sub>2</sub> , (95% CI)	0.654 (0.459 to 0.850)	0.639 (0.439 to 0.839)	0.692 (0.526 to 0.858)
VsO <sub>2</sub> , (95% CI)	0.824 (0.672 to 0.975)	0.533 (0.320 to 0.746)	0.771 (0.639 to 0.904)
A-V sO <sub>2</sub> , (95% CI)	0.827 (0.679 to 0.976)	0.647 (0.450 to 0.845)	0.852 (0.741 to 0.962)
OE, (95% CI)	<b>0.849 (0.705 to 0.994)</b>	0.557 (0.346 to 0.768)	<b>0.855 (0.739 to 0.972)</b>
GCL+IPL, (95% CI)	0.634 (0.442 to 0.826)	0.737 (0.551 to 0.923)	0.716 (0.564 to 0.868)
cpRNFL, (95% CI)	0.629 (0.425 to 0.832)	<b>0.775 (0.613 to 0.936)</b>	0.754 (0.608 to 0.900)

Receiver operating characteristic (ROC) analysis is based on univariate logistic prediction. The maximum ROC in each column value was bolded.

## Discussion

This is the first study to investigate macular sO<sub>2</sub> of glaucoma subjects using the retinal oximetry of dual-channel VIS-OCT. VIS-OCT uniquely allow scanning of the macular arterioles and venules, calculating macular sO<sub>2</sub>, without confounding signals from other layers that plaque the fundus-based oximetry. We found macular sO<sub>2</sub> is correlated with severity of glaucoma and performs better separating GS/PPG from normal eyes than GCL+NFL and cpRNFL thinning. Within the PG group, AsO<sub>2</sub> is significantly correlated with GCL+NFL and cpRNFL, which is contributed by the more severely damaged lower hemifield. This correlation analysis strongly indicates that the macular sO<sub>2</sub> is associated with glaucomatous macular tissue loss. Importantly, macular VsO<sub>2</sub> and A-V sO<sub>2</sub> have significant differences when comparing normal with GS/PPG eyes, even prior to detectable thinning and visual field damage.

All existing literatures in the scope of sO<sub>2</sub> in glaucoma reported global measurements from the major vessels in the parapapillary region around ONH, which is difficult to extrapolate to macular sO<sub>2</sub> in this presented study<sup>31-38</sup>. Nonetheless, those reports showed rather consistent AsO<sub>2</sub> in major retinal arterioles, or in rare case higher AsO<sub>2</sub> in PG subjects. While the inclusion criterion and study population differ, those reports also showed decreased global A-V sO<sub>2</sub> in glaucoma, underlay by reduced metabolic demand with RGCs loss. Remarkably, we observed a similar reduction of A-V sO<sub>2</sub>, as well as OE at a more localized macular region. Given that RGCs are most abundant in macula, and they are major energy consumer in inner retina, our finding suggests that early RGC/RNFL damage may be manifested with reduction of oxygen metabolism in macular region, correlated with the thinning of GCL+IPL+RNFL. It is worth noting that, in contrary to an unchanged (or slightly increased) global AsO<sub>2</sub> in previous reports<sup>32-38</sup>, we found that macular AsO<sub>2</sub> significantly declined with severity among three groups.

Both AsO<sub>2</sub> and A-V sO<sub>2</sub> are significantly correlated with GCL+NFL and cpRNFL either among three groups or within PG eyes. In addition, in PG eyes, the correlation is primarily driven by the more severely damaged lower hemifield. To our surprise, we didn't find significant correlation between VsO<sub>2</sub> and GCL+NFL or cpRNFL, whether among three groups or within PG eyes. Upon closer examination of the data, VsO<sub>2</sub> increases significantly from normal to GS/PPG, but remains relatively consistent between two more severer groups. We speculate that VsO<sub>2</sub> is more significantly impacted in early stage of tissue atrophy in glaucoma, while the AsO<sub>2</sub> continues to decline along with the progressing severity. A more comprehensive set of including macular blood flow would further elucidate the speculation.

We found no significant correlation of global MD to any macular sO<sub>2</sub> parameters or GCL+IPL/cpRNFL. We note that 24-2 VFT only has 4 measurements points within 25° center viewing angle in macula, and thus under sampling the macular region which may lead to large variations<sup>16</sup>. Also, as the RGCs are highly redundant in macula, up to 30% of RGCs loss can proceed to visual field damage<sup>10</sup>. Therefore, it is not totally surprising that correlations between MD and other variables are not statistically significant within this study population.

There were several limitations of this study that we would like to address in future studies. First, the cohort size was limited. A larger subject population would be beneficial for multivariable statistical analysis. Second, the implementation of visible light can cause discomfort to some subjects, and it is more susceptible to cataracts and aging eyes. To address this, we will further optimize the imaging device including eye tracking and automatic focusing, which will significantly reduce the exposure to the visible light. Third, the current data processing used manual segmentations for selecting vessel ROIs, as well as assignment of arterioles and venules based on experiences. Automatic algorithms for segmentation and vessel tracing will be developed to streamline the data processing, to achieve real time sO<sub>2</sub> calculation. Finally, to balance the image depth range, the device used in this study has a relatively short visible light bandwidth of 40nm. Our new-generation VIS-OCT device improved the resolution with wider wavelength bands and expanded the working range<sup>39</sup>. With a more precise extracted spectra, it will help increase the calculation accuracy of sO<sub>2</sub> in future studies.

In conclusion, we reported the first study of VIS-OCT to investigate the macular sO<sub>2</sub> in glaucoma subjects. With the high resolution in both axial and lateral directions, VIS-OCT was a powerful tool to characterize macular sO<sub>2</sub> and identify the significant differences between the normal, GS/PPG and PG subjects. The measurement of sO<sub>2</sub> can potentially act as a marker to provide the early diagnosis and monitor the progress of glaucoma disease.

## Acknowledgments

The study is supported by NIH funding R01NS108464, R01EY032163, and R01EY034607.

## Contribution

JY supervised the project. JW performed the analysis. NS, MF and MD assisted in subject recruitment. All authors have read and approved the final manuscript.

## Reference

1. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. *Ophthalmology*. 2014;121(11):2081-2090.
2. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. *Br J Ophthalmol*. 2006;90(3):262-267.
3. Miki A, Medeiros FA, Weinreb RN, et al. Rates of retinal nerve fiber layer thinning in glaucoma suspect eyes. *Ophthalmology*. 2014;121(7):1350-1358.
4. Mwanza JC, Durbin MK, Budenz DL, et al. Glaucoma diagnostic accuracy of ganglion cell–inner plexiform layer thickness: comparison with nerve fiber layer and optic nerve head. *Ophthalmology*. 2012;119(6):1151-1158.

5. Banitt MR, Ventura LM, Feuer WJ, et al. Progressive loss of retinal ganglion cell function precedes structural loss by several years in glaucoma suspects. *Invest Ophthalmol Vis Sci*. 2013;54(3):2346-2352.
6. Ventura LM, Sorokac N, De Los Santos R, Feuer WJ, Porciatti V. The relationship between retinal ganglion cell function and retinal nerve fiber thickness in early glaucoma. *Invest Ophthalmol Vis Sci*. 2006;47(9):3904-3911.
7. Calkins DJ, Horner PJ. The cell and molecular biology of glaucoma: axonopathy and the brain. *Invest Ophthalmol Vis Sci*. 2012;53(5):2482-2484.
8. Hood DC, Raza AS, de Moraes CGV, Liebmann JM, Ritch R. Glaucomatous damage of the macula. *Prog Retin Eye Res*. 2013;32:1-21.
9. Curcio CA, Allen KA. Topography of ganglion cells in human retina. *J Comp Neurol*. 1990;300(1):5-25.
10. Quigley HA, Dunkelberger GR, Green WR. Retinal ganglion cell atrophy correlated with automated perimetry in human eyes with glaucoma. *Am J Ophthalmol*. 1989;107(5):453-464.
11. Hood DC, Slobodnick A, Raza AS, de Moraes CG, Teng CC, Ritch R. Early glaucoma involves both deep local, and shallow widespread, retinal nerve fiber damage of the macular region. *Invest Ophthalmol Vis Sci*. 2014;55(2):632-649.
12. Chua J, Tan B, Ke M, et al. Diagnostic ability of individual macular layers by spectral-domain OCT in different stages of glaucoma. *Ophthalmol Glaucoma*. 2020;3(5):314-326.
13. Kamalipour A, Moghimi S, Jacoba CM, et al. Measurements of OCT angiography complement OCT for diagnosing early primary open-angle glaucoma. *Ophthalmol Glaucoma*. 2022;5(3):262-274.
14. Hou H, Moghimi S, Kamalipour A, et al. Macular thickness and microvasculature loss in glaucoma suspect eyes. *Ophthalmol Glaucoma*. 2022;5(2):170-178.
15. Takusagawa HL, Liu L, Ma KN, et al. Projection-resolved optical coherence tomography angiography of macular retinal circulation in glaucoma. *Ophthalmology*. 2017;124(11):1589-1599.
16. De Moraes CG, Hood DC, Thenappan A, et al. 24-2 visual fields miss central defects shown on 10-2 tests in glaucoma suspects, ocular hypertensives, and early glaucoma. *Ophthalmology*. 2017;124(10):1449-1456.
17. Wong-Riley M. Energy metabolism of the visual system. *Eye Brain*. Published online 2010:99-116.
18. Casson RJ, Chidlow G, Crowston JG, Williams PA, Wood JP. Retinal energy metabolism in health and glaucoma. *Prog Retin Eye Res*. 2021;81:100881.
19. Pi S, Hormel TT, Wei X, et al. Retinal capillary oximetry with visible light optical coherence tomography. *Proc Natl Acad Sci*. 2020;117(21):11658-11666.

20. Yi J, Liu W, Chen S, et al. Visible light optical coherence tomography measures retinal oxygen metabolic response to systemic oxygenation. *Light Sci Appl*. 2015;4(9):e334-e334.
21. Chong SP, Zhang T, Kho A, Bernucci MT, Dubra A, Srinivasan VJ. Ultrahigh resolution retinal imaging by visible light OCT with longitudinal achromatization. *Biomed Opt Express*. 2018;9(4):1477-1491.
22. Wang J, Baker A, Subramanian ML, et al. Simultaneous visible light optical coherence tomography and near infrared OCT angiography in retinal pathologies: A case study. *Exp Biol Med*. 2022;247(5):377-384.
23. Chong SP, Bernucci M, Radhakrishnan H, Srinivasan VJ. Structural and functional human retinal imaging with a fiber-based visible light OCT ophthalmoscope. *Biomed Opt Express*. 2017;8(1):323-337.
24. Wang J, Song W, Sadlak N, Fiorello MG, Desai M, Yi J. A Baseline Study of Oxygen Saturation in Parafoveal Vessels Using Visible Light Optical Coherence Tomography. *Front Med*. 2022;9.
25. Hardarson SH. Retinal oximetry. *Acta Ophthalmol (Copenh)*. 2013;91(thesis2):1-47.
26. Hardarson SH, Harris A, Karlsson RA, et al. Automatic retinal oximetry. *Invest Ophthalmol Vis Sci*. 2006;47(11):5011-5016.
27. Garg AK, Knight D, Lando L, Chao DL. Advances in retinal oximetry. *Transl Vis Sci Technol*. 2021;10(2):5-5.
28. Song W, Shao W, Yi W, et al. Visible light optical coherence tomography angiography (vis-OCTA) facilitates local microvascular oximetry in the human retina. *Biomed Opt Express*. 2020;11(7):4037-4051.
29. Song W, Zhou L, Zhang S, Ness S, Desai M, Yi J. Fiber-based visible and near infrared optical coherence tomography (vnOCT) enables quantitative elastic light scattering spectroscopy in human retina. *Biomed Opt Express*. 2018;9(7):3464-3480.
30. Song W, Zhang S, Kim YM, et al. Visible light optical coherence tomography of peripapillary retinal nerve fiber layer reflectivity in glaucoma. *Transl Vis Sci Technol*. 2022;11(9):28-28.
31. Shahidi AM, Hudson C, Tayyari F, Flanagan JG. Retinal oxygen saturation in patients with primary open-angle glaucoma using a non-flash hyperspectral camera. *Curr Eye Res*. 2017;42(4):557-561.
32. Shimazaki T, Hirooka K, Nakano Y, et al. Relationship between oxygen saturation of the retinal vessels and visual field defect in glaucoma patients: comparison with each hemifield. *Acta Ophthalmol (Copenh)*. 2016;94(8):e683-e687.
33. Olafsdottir OB, Hardarson SH, Gottfredsdottir MS, Harris A, Stefánsson E. Retinal oximetry in primary open-angle glaucoma. *Invest Ophthalmol Vis Sci*. 2011;52(9):6409-6413.

34. Vandewalle E, Abegao Pinto L, Olafsdottir OB, et al. Oximetry in glaucoma: correlation of metabolic change with structural and functional damage. *Acta Ophthalmol (Copenh)*. 2014;92(2):105-110.
35. Ramm L, Jentsch S, Peters S, Augsten R, Hammer M. Investigation of blood flow regulation and oxygen saturation of the retinal vessels in primary open-angle glaucoma. *Graefes Arch Clin Exp Ophthalmol*. 2014;252(11):1803-1810.
36. Mordant D, Al-Abboud I, Muyo G, Gorman A, Harvey A, McNaught A. Oxygen saturation measurements of the retinal vasculature in treated asymmetrical primary open-angle glaucoma using hyperspectral imaging. *Eye*. 2014;28(10):1190-1200.
37. Olafsdottir OB, Vandewalle E, Pinto LA, et al. Retinal oxygen metabolism in healthy subjects and glaucoma patients. *Br J Ophthalmol*. 2014;98(3):329-333.
38. Ramm L, Jentsch S, Peters S, Sauer L, Augsten R, Hammer M. Dependence of diameters and oxygen saturation of retinal vessels on visual field damage and age in primary open-angle glaucoma. *Acta Ophthalmol (Copenh)*. 2016;94(3):276-281.
39. Wang J, Nolen S, Song W, Shao W, Yi W, Yi J. Second-generation dual-channel visible light optical coherence tomography enables wide-field, full-range, and shot-noise limited retinal imaging. *bioRxiv*. Published online 2022.